A Study Assessing the Safety, Tolerability, and Efficacy of RG6147 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

• Status: Recruiting
• Trial end date: 2024-06-03

Summary

This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of RG6147 administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) compared with sham control. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT03972709 (GR42558) and receive open-label RG6147 injections.

• Phase: Phase 2

Details

• Lead Sponsor: Genentech, Inc.